Global Calcium is one of the leading manufacturers and exporters of
Cytarabine CAS no. 147-94-4, API, (Active Pharmaceutical Ingredient). We support the customers with exhaustive documentation. As a USDMF & EU-GMP certified global company and an established hallmark for pharmaceutical standards, Global Calcium has stood the test of time since its inception in 1979.
As manufacturer of Cytarabine we hereby state the following facts about the drug:
Cytarabine (also known as cytarabine arabinoside or ARA-C) is an antimetabolite chemotherapy medication used to treat acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), meningeal leukemia, and other cancers. It is a pyrimidine analog that works by interfering with the production of DNA in cancer cells. Cytarabine is typically given as an injection into a vein or into the cerebrospinal fluid.
For the treatment of acute non-lymphocytic leukemia, acute lymphocytic leukemia and blast phase of chronic myelocytic leukemia.
Mechanism of action
Cytarabine acts through direct DNA damage and incorporation into DNA. Cytarabine is cytotoxic to a wide variety of proliferating mammalian cells in culture. It exhibits cell phase specificity, primarily killing cells undergoing DNA synthesis (S-phase) and under certain conditions blocking the progression of cells from the G1 phase to the S-phase. Although the mechanism of action is not completely understood, it appears that cytarabine acts through the inhibition of DNA polymerase. A limited, but significant, incorporation of cytarabine into both DNA and RNA has also been reported.
Global Calcium is a leading manufacturer of this drug. We manufacture this pharmaceutical drug and make it available to domestic and overseas market